ABSTRACT, Seventeen subjects with chronic severe asthma completed a 48 week prospective, double blind study with crossover of treatment at 24 weeks, in which triamcinolone acetonide 80 mg intramuscularly every four weeks was compared with oral prednisolone 10 mg daily. Spirometry, twice daily measurements of peak expiratory flow rate, and self assessment of asthma symptom scores showed significant improvement during triamcinolone treatment; less extra prednisolone was required and there was significant weight loss. Two patients withdrew, one because of dissatisfaction with prednisolone and one because of side effects while taking triamcinolone. Three were withdrawn, one with proximal muscle weakness and two because of intercurrent illness. Adrenal suppression, bruising, and hirsuitism were worse with triamcinolone, other side effects being comparable. On completion of the study 16 of the 17 patients opted to continue taking triamcinolone acetonide. This treatment is an important addition to the therapeutic options available for chronic severe asthma.
The introduction of corticosteroids revolutionised the treatment of asthma in the 1950s' and inhaled corticosteroids subsequently produced further substantial benefits for many asthmatics by reducing or abolishing the need for regular oral corticosteroid treatment.2 Some asthmatic patients continue to have symptoms with persistently poor ventilatory function despite continuous oral corticosteroid treatment. These patients are frequently much disabled by their disease and improve appreciably only with unacceptably high doses of corticosteroids. They therefore pose both a therapeutic dilemma and an important challenge in asthma research.
We have treated such patients with intramuscular triamcinolone acetonide for some years and have formed the impression that this often has considerable advantages for the patient, a suggestion supported by two previous studies.34 To confirm this, we selected patients with chronic severe asthma who required at least 10 mg of prednisolone as daily maintenance treatment in addition to inhaled corticosteroids, and compared monthly intramuscular triamcinolone acetonide with daily oral prednisolone in a study using objective measurements and diary card assessment.
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Methods
Twenty two patients agreed to take part in the study. All had longstanding asthma and had previously shown considerable variability in ventilatory function spontaneously and at least 20% improvement in FEV, with corticosteroid treatment. All had required a minimum of 10 mg oral prednisolone daily for several years as well as inhaled beclomethasone 400 ,ug daily; with this combination all had peak flow rates less than 70% of predicted. None had suffered an exacerbation of symptoms or had needed to increase the dose of prednisolone in the four weeks before entering the study.
All patients gave written consent and the study protocol was approved by the local ethical committee. Patients were instructed in the completion of a diary card, recording twice daily peak flow rate (best of three blows), day and night symptom scores (from 0 = "no symptoms" to 4 = "symptoms requiring emergency treatment"'), extra treatment required, and any other comments. They were examined every four weeks with measurement of FEV, FVC, weight, and blood pressure; urine analysis; and fundoscopy. Proximal muscle weakness was tested by asking the patient to stand upright from the squatting position five times in quick succession. Cushingoid appearance, bruising, and peripheral oedema were scored in terms of severity on a five point scale. 840 Intramuscular triamcinolone acetonide in chronic severe asthma In addition, on entry and at 12, 24, 36, and 48 weeks a full blood count was done and concentrations of electrolytes, urea, calcium, phoshate, and alkaline phosphatase were checked. A short tetracosactrin test (250 ,g given by intramuscular injection with plasma cortisol recorded at 0 and 30 minutes) was performed on entry and at the end of each 24 week period of treatment.
We used a 48 week double blind, placebo controlled study design, with crossover of treatment after 24 weeks. Active treatment-triamcinolone acetonide 80 mg intramuscularly every four weeks or prednisolone 10 mg orally each day-was given to all patients along with the corresponding placebo tablets or placebo injections. Patients were randomly allocated in equal numbers to the initial active treatment and instructed to take their trial tablets early each morning. After the 48 weeks all subjects were asked to state whether they preferred the first or second 24 week treatment period, after which the code was broken.
Subjects were instructed to treat an exacerbation during the trial by taking extra prednisolone, 20 mg/day for at least five days, and then reduce it in their usual way. All were supplied with labelled active prednisolone for this purpose. Other treatment, such as inhaled or oral sympathomimetics, was continued unchanged throughout the study. All changes in treatment were recorded on the diary cards and at each clinic visit the remaining tablets in both the " triar' and the " active" bottles were counted.
The data were entered into a Prime 750 computer. Statistical methods were primarily descriptive, paired t tests being used to test the significance of any differences observed.
Results
Twenty two subjects, 15 men and seven women (mean age 56 years, range 23-71) started the study. Two smoked 10 cigarettes daily and three were ex-smokers. Three were withdrawn from the study: one suffered a myocardial infarct 20 weeks after starting the study; one died of bronchial carcinoma, which was diagnosed at 28 weeks; and one noted increasing proximal muscle weakness at 40 weeks (16 weeks after starting triamcinolone). Two others withdrew, one because of no improvement after eight weeks of prednisolone and one because of weight loss and muscle weakness after 12 weeks of triamcinolone. Thus 17 subjects completed the study but sufficient data were collected on the patient who completed 40 weeks to permit his inclusion in the analysis.
PEAK FLOW RATES: DIFFERENCES BETWEEN TREATMENTS
The mean results of the peak flow recordings are shown in the figure. The patients who started with Those subjects receiving triamcinolone had consistently higher readings than those receiving prednisolone throughout the first 24 weeks. After the crossover the peak flow rates of those now having triamcinolone climbed above those of the subjects now having prednisolone. The overall mean peak flow rates (PFR) were significantly higher with triamcinolone than with prednisolone (p < 0.001) both in the morning and in the evening (table 1) . Similar results were obtained when the first eight weeks of each 24 week period were excluded to avoid "carryover' effects.
BUILD UP EFFECT
The figure also illustrates a progressive rise in peak flow rates in those subjects taking triamcinolone, both in the first and in the second periods. Peak flow rates fell, however, between the fifth and sixth four week cycles, again in both periods. A significant increase was found in the morning readings during triamcinolone treatment when the mean peak flows in the first and second months were compared with those of the fourth and fifth months (p < 0.05, Sixteen of the 17 patients who completed the trial preferred the triamcinolone period and opted to continue with that treatment.
Discussion
This study confirms that triamcinolone acetonide 80 mg, given intramuscularly every four weeks, has certain advantages over oral prednisolone (10 mg daily) in the treatment of chronic severe asthma. Pulmonary function improved, symptoms of asthma decreased, less extra prednisolone was required, and in this group of patients side effects were no more troublesome. Moreover, most patients preferred this treatment.
These findings support those of previous investigators in showing that 80 mg of triamcinolone Conversion: SI to traditional units-Cortisol: 1 nmoVlI = 0.036 lAg/100 ml; urea: 1 mmol/l = 6.024 mg/100 ml; potassium: 1 mmol/l = ' was much increased while the systemic glucocorticoid effects were little changed. A vasoconstriction assay on human skin using alcohol solutions of corticosteroids under occlusive dressings showed that the relative topical potency of dexamethasone to triamcinolone acetonide to beclomethasone dipropionate was 0.8:100:500.12 Given intravenously, however, beclomethasone dipropionate was equivalent to dexamethasone in lowering cortisol (implying a similar systemic glucocorticoid effect). While triamcinolone acetonide is about 100 times more potent than dexamethasone on human skin, its relative potency with respect to reduction of plasma cortisol does not appear to have been investigated.
One of the actions of corticosteroids leads to the synthesis of a factor that blocks phospholipase A2, thus preventing the biosynthesis of a whole cascade of lipid mediators.'3 The potency of this inhibition closely parallels anti-inflammatory activity. If therefore a local anti-inflammatory effect within the airway were a critical factor in the unique efficacy of
